Novavax, Inc. (NVAX)
| Previous close | 13.01 |
| Open | 13.05 |
| Bid | 14.20 x 1500 |
| Ask | 16.28 x 100 |
| Day's range | 12.68 - 14.45 |
| 52-week range | 3.53 - 15.00 |
| Volume | |
| Avg. volume | 12,932,888 |
| Market cap | 2.098B |
| Beta (5Y monthly) | 1.62 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.05 |
| Earnings date | 06 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 18.00 |
ReutersShah Capital ends campaign against Novavax board after Sanofi deal
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation. Novavax, which struggled to get its protein-based vaccine to the market in a timely manner, also removed a warning notice from February last year that raised doubts about it being in business after the deal. The fund, which owns an about 7.8% stake in Novavax, reiterated that the Sanofi agreement was a "long-awaited step in the right direction".
GlobeNewswireShah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meeting
Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value Still Remains to Be Unlocked at Novavax Still Believes Novavax Would Benefit from Stockholder Representative on Board RALEIGH, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Shah Capital Management, Inc. (together with its affiliates, “Shah Capital,” “we” or “our”) collectively beneficially owns ~7.9% of the outstanding common stock of Novavax, Inc. (NASDAQ: NVAX) (“Novavax” or the “Company”), making it
ZacksThe Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers are included in this Analyst Blog.
